Yahoo Finance32m
3 US Growth Stocks With Insider Ownership As High As 37%
Overview: Corcept Therapeutics Incorporated is involved in the discovery and development of drugs for treating severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United ...
Truist Financial Sticks to Their Buy Rating for Argenx Se (ARGX)
In a report released yesterday, Joon Lee from Truist Financial maintained a Buy rating on Argenx Se (ARGX – Research Report), with a ...
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out?
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Corcept Stock At New High; Will The Upcoming Regulatory And Clinical Trial Catalysts Take It Higher?
Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...
bovnews22h
Corcept Therapeutics Incorporated (CORT)’s Stock Surge: What You Need to Know
On Monday, Corcept Therapeutics Incorporated (CORT) stock saw a modest uptick, ending the day at $50.06 which represents a slight increase of $2.44 or 5.12% from the prior close of $47.62. The stock ...